Literature DB >> 8878580

Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.

V Revel-Viravau1, Q C Truong, N Moreau, V Jarlier, W Sougakoff.   

Abstract

We determined the nucleotide sequence of a 6-kb DNA region harboring the recF, orf192, gyrB, and gyrA genes from Mycobacterium smegmatis mc(2)155. The amino acid sequences deduced from gyrA and gyrB displayed 89 and 86% identity, respectively, with the DNA gyrase from Mycobacterium tuberculosis, and 67 and 65% identity, respectively, with that from Streptomyces coelicolor. An open reading frame encoding the C-terminal region of the M. smegmatis RecF polypeptide was found upstream from gyrB and was 57% identical to the open reading frame encoding the C-terminal region of the S. coelicolor RecF protein. The gene orf192 was identified between recF and gyrB and was 39% identical to orf191 found in S. coelicolor in the recF-gyrB region. The M. smegmatis DNA gyrase, which was purified by affinity chromatography on novobiocin-Sepharose, consisted of two polypeptides with apparent molecular masses of 98 and 80 kDa. Determination of the N-terminal amino acid sequence of the B subunit confirmed GTG as the start codon in gyrB. Analysis of the supercoiling activity of the enzyme indicated that the M. smegmatis DNA gyrase was characterized by a specific activity equivalent to that of the Escherichia coli DNA gyrase. Inhibition of this activity by 4-quinolones was investigated by determining the 50% inhibitory concentrations (IC50S) of nalidixic acid, ofloxacin, and ciprofloxacin. The results indicated that the inhibitory activities of these drugs against the M. smegmatis DNA gyrase were markedly lower than those previously reported for the E. coli DNA gyrase. The results also suggested that the higher levels of activity of ofloxacin and ciprofloxacin against M. smegmatis (MICs, 0.5 to 1 microgram/ml), in contrast to that of nalidixic acid (MIC, 256 micrograms/ml), could be related to the higher inhibitory activities of fluoroquinolones against the DNA gyrase from this species (IC50S, 7 to 14 micrograms/ml) compared with that of nalidixic acid (IC50, 1,400 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878580      PMCID: PMC163472     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  DNA sequence and transcription of the region upstream of the E. coli gyrB gene.

Authors:  T Adachi; K Mizuuchi; R Menzel; M Gellert
Journal:  Nucleic Acids Res       Date:  1984-08-24       Impact factor: 16.971

2.  Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus.

Authors:  S M Brockbank; P T Barth
Journal:  J Bacteriol       Date:  1993-06       Impact factor: 3.490

3.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

Authors:  E Cambau; W Sougakoff; M Besson; C Truffot-Pernot; J Grosset; V Jarlier
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

5.  Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.

Authors:  S Bazile; N Moreau; D Bouzard; M Essiz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Expression and analysis of two gyrB genes from the novobiocin producer, Streptomyces sphaeroides.

Authors:  A S Thiara; E Cundliffe
Journal:  Mol Microbiol       Date:  1993-05       Impact factor: 3.501

7.  Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones.

Authors:  V Revel; E Cambau; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.

Authors:  A Kureishi; J M Diver; B Beckthold; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Molecular cloning of gyrA and gyrB genes of Mycobacterium tuberculosis: analysis of nucleotide sequence.

Authors:  K Madhusudan; V Ramesh; V Nagaraja
Journal:  Biochem Mol Biol Int       Date:  1994-07

10.  Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria.

Authors:  E Cambau; W Sougakoff; V Jarlier
Journal:  FEMS Microbiol Lett       Date:  1994-02-01       Impact factor: 2.742

View more
  5 in total

1.  Purification, crystallization and preliminary X-ray crystallographic studies of the Mycobacterium tuberculosis DNA gyrase ATPase domain.

Authors:  Mélanie Roué; Alka Agrawal; Craig Volker; Danuta Mossakowska; Claudine Mayer; Benjamin D Bax
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-05-25

Review 2.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

3.  Determination of DNA sequences required for regulated Mycobacterium tuberculosis RecA expression in response to DNA-damaging agents suggests that two modes of regulation exist.

Authors:  F Movahedzadeh; M J Colston; E O Davis
Journal:  J Bacteriol       Date:  1997-06       Impact factor: 3.490

4.  ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.

Authors:  E Varon; C Janoir; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

5.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.